French VC Surge: Jeito Capital's $1.2 Billion Breakout

France is making headlines as Jeito Capital raises $1.2 billion, propelling the country’s VC landscape past the entire 2025 haul with a first‑half total of €2.4 billion.

Jeito Capital’s $1.2 Billion Milestone

■Jeito II’s close represents 40% of the year‑to‑date total.

■This biopharma‑focused fund set a new benchmark for single‑fund performance in 2026.

Kurma Biofund IV & Bpifrance’s Collaborative Play

■€215 million raised, backed by Eurazeo, CSL, the European Investment Fund, and Bpifrance.

■A testament to the growing synergy in biotech venture capital.

State‑Backed Momentum: Bpifrance & Tibi 2’s Strategic Shift

■Bpifrance accounts for roughly 30% of France’s seed and early‑stage VC spend.

■A €10 billion AI commitment in February 2025 underscored its tech‑centric focus.

■Tibi 2 brings together 30+ institutional players pledging €7 billion through 2026.

Future Funds: Atlantic Vantage Point & Bpifrance’s New Frontier

■Atlantic Vantage Point is targeting €1.5 billion, poised to be the largest open VC fund.

■Bpifrance Large Venture Fund 3 aims for €750 million.

Markets observe that France’s blend of state‑led VC initiatives and large‑scale biopharma fundraising is recalibrating the European risk‑capital ecosystem. Jeito’s performance signals a new era of high‑value deals, while government involvement remains a pivotal catalyst for sustained growth.